Bayer AG (NASDAQ:BAYRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “Bayer surpassed earnings estimates but missed revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business at Consumer Health decreased, primarily due to the difficult market environment in the U.S. Based on this, the company lowered its revenue and earnings outlook for 2017. The company is facing generic threats/competition for many of its products including the Yaz franchise (oral contraceptives). The genericization of key drugs would negatively impact revenues. Nevertheless, the company is looking forward to acquire Monsanto Company in a deal worth approximately $66 billion. With the acquisition, the combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. Yet, Bayer’s shares have outperformed the Zacks classified industry year to date.”

Separately, Berenberg Bank cut Bayer AG from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $111.00.

Bayer AG (NASDAQ:BAYRY) traded up 1.81% on Friday, reaching $129.41. The company’s stock had a trading volume of 13,970 shares. The stock has a market cap of $112.86 billion and a P/E ratio of 19.03. Bayer AG has a one year low of $91.53 and a one year high of $139.04. The stock has a 50-day moving average of $127.07 and a 200-day moving average of $123.07.

Bayer AG (NASDAQ:BAYRY) last released its quarterly earnings results on Thursday, July 27th. The company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.12. The company had revenue of $13.41 billion during the quarter, compared to analysts’ expectations of $14.45 billion. Bayer AG had a return on equity of 13.03% and a net margin of 10.90%. On average, analysts predict that Bayer AG will post $8.80 EPS for the current fiscal year.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/25/bayer-ag-bayry-stock-rating-upgraded-by-zacks-investment-research.html.

Bayer AG Company Profile

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Analyst Recommendations for Bayer AG (NASDAQ:BAYRY)

Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.